The Filings Report

West Pharmaceutical Services, Inc.

WSTNYSECIK 105770Healthcare / Medical Devicesfiscal year ends December70 quarters since 2009

Revenue, Q3 FY2026
$875M
+8.7% on Q3 FY2025
Net income
$214M
+52.9% on Q3 FY2025
Free cash flow
$150M
+12.3% on Q3 FY2025
Diluted EPS
$3.02
+57.3% on Q3 FY2025
Revenue, TTM
$3.4B
trailing four quarters
Net margin, TTM
18.8%
net income $639M
Free cash flow, TTM
$453M
$655M less $201M capex
Cash and equivalents
$464M
long-term debt $203M, Sep 30, 2026
Shares, 12-month change
−3.2%
70M shares, Sep 30, 2026
Buybacks, TTM
$685M
2.4% of market value
Dividends, TTM
$63M
0.2% of market value
Market value
$28.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, West Pharmaceutical Services, Inc. reported revenue of $875M, +8.7% on Q3 FY2025, and net income of $214M (+52.9%). Operating margin was 30.6%. Free cash flow, operating cash flow less capital expenditures, was $150M ($190M less $39M). Diluted earnings per share were $3.02.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 29, 2026.

Revenue and net incomeRevenueNet income
$0$250M$500M$750M$1.0BQ4'22, Revenue: $709MQ4'22, Net income: $103MQ4'22Q1'23, Revenue: $717MQ1'23, Net income: $140MQ1'23Q2'23, Revenue: $754MQ2'23, Net income: $155MQ2'23Q3'23, Revenue: $747MQ3'23, Net income: $161MQ3'23Q4'23, Revenue: $732MQ4'23, Net income: $137MQ4'23Q1'24, Revenue: $695MQ1'24, Net income: $115MQ1'24Q2'24, Revenue: $702MQ2'24, Net income: $111MQ2'24Q3'24, Revenue: $747MQ3'24, Net income: $136MQ3'24Q4'24, Revenue: $749MQ4'24, Net income: $130MQ4'24Q1'25, Revenue: $698MQ1'25, Net income: $90MQ1'25Q2'25, Revenue: $767MQ2'25, Net income: $132MQ2'25Q3'25, Revenue: $805MQ3'25, Net income: $140MQ3'25Q4'25, Revenue: $805MQ4'25, Net income: $132MQ4'25Q1'26, Revenue: $845MQ1'26, Net income: $139MQ1'26Q2'26, Revenue: $872MQ2'26, Net income: $154MQ2'26Q3'26, Revenue: $875MQ3'26, Net income: $214MQ3'26$0$250M$500M$750M$1.0BQ4'22, Revenue: $709MQ4'22, Net income: $103MQ1'23, Revenue: $717MQ1'23, Net income: $140MQ1'23Q2'23, Revenue: $754MQ2'23, Net income: $155MQ3'23, Revenue: $747MQ3'23, Net income: $161MQ3'23Q4'23, Revenue: $732MQ4'23, Net income: $137MQ1'24, Revenue: $695MQ1'24, Net income: $115MQ1'24Q2'24, Revenue: $702MQ2'24, Net income: $111MQ3'24, Revenue: $747MQ3'24, Net income: $136MQ3'24Q4'24, Revenue: $749MQ4'24, Net income: $130MQ1'25, Revenue: $698MQ1'25, Net income: $90MQ1'25Q2'25, Revenue: $767MQ2'25, Net income: $132MQ3'25, Revenue: $805MQ3'25, Net income: $140MQ3'25Q4'25, Revenue: $805MQ4'25, Net income: $132MQ1'26, Revenue: $845MQ1'26, Net income: $139MQ1'26Q2'26, Revenue: $872MQ2'26, Net income: $154MQ3'26, Revenue: $875MQ3'26, Net income: $214MQ3'26

Net income losses drawn in red.

Free cash flow
$0$50M$100M$150M$200MQ4'22, Free cash flow: $136MQ4'22Q1'23, Free cash flow: $56MQ1'23Q2'23, Free cash flow: $94MQ2'23Q3'23, Free cash flow: $134MQ3'23Q4'23, Free cash flow: $130MQ4'23Q1'24, Free cash flow: $28MQ1'24Q2'24, Free cash flow: $65MQ2'24Q3'24, Free cash flow: $99MQ3'24Q4'24, Free cash flow: $85MQ4'24Q1'25, Free cash flow: $58MQ1'25Q2'25, Free cash flow: $102MQ2'25Q3'25, Free cash flow: $134MQ3'25Q4'25, Free cash flow: $175MQ4'25Q1'26, Free cash flow: $47MQ1'26Q2'26, Free cash flow: $81MQ2'26Q3'26, Free cash flow: $150MQ3'26$0$50M$100M$150M$200MQ4'22, Free cash flow: $136MQ1'23, Free cash flow: $56MQ1'23Q2'23, Free cash flow: $94MQ3'23, Free cash flow: $134MQ3'23Q4'23, Free cash flow: $130MQ1'24, Free cash flow: $28MQ1'24Q2'24, Free cash flow: $65MQ3'24, Free cash flow: $99MQ3'24Q4'24, Free cash flow: $85MQ1'25, Free cash flow: $58MQ1'25Q2'25, Free cash flow: $102MQ3'25, Free cash flow: $134MQ3'25Q4'25, Free cash flow: $175MQ1'26, Free cash flow: $47MQ1'26Q2'26, Free cash flow: $81MQ3'26, Free cash flow: $150MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$250M$500M$750M$1.0BQ4'22, Cash and equivalents: $894MQ4'22, Long-term debt: $207MQ4'22Q1'23, Cash and equivalents: $886MQ1'23, Long-term debt: $206MQ1'23Q2'23, Cash and equivalents: $796MQ2'23, Long-term debt: $206MQ2'23Q3'23, Cash and equivalents: $899MQ3'23, Long-term debt: $152MQ3'23Q4'23, Cash and equivalents: $854MQ4'23, Long-term debt: $73MQ4'23Q1'24, Cash and equivalents: $602MQ1'24, Long-term debt: $73MQ1'24Q2'24, Cash and equivalents: $446MQ2'24, Long-term debt: $73MQ2'24Q3'24, Cash and equivalents: $491MQ3'24, Long-term debt: $203MQ3'24Q4'24, Cash and equivalents: $485MQ4'24, Long-term debt: $203MQ4'24Q1'25, Cash and equivalents: $404MQ1'25, Long-term debt: $203MQ1'25Q2'25, Cash and equivalents: $510MQ2'25, Long-term debt: $203MQ2'25Q3'25, Cash and equivalents: $629MQ3'25, Long-term debt: $203MQ3'25Q4'25, Cash and equivalents: $791MQ4'25, Long-term debt: $203MQ4'25Q1'26, Cash and equivalents: $521MQ1'26, Long-term debt: $203MQ1'26Q2'26, Cash and equivalents: $436MQ2'26, Long-term debt: $203MQ2'26Q3'26, Cash and equivalents: $464MQ3'26, Long-term debt: $203MQ3'26$0$250M$500M$750M$1.0BQ4'22, Cash and equivalents: $894MQ4'22, Long-term debt: $207MQ1'23, Cash and equivalents: $886MQ1'23, Long-term debt: $206MQ1'23Q2'23, Cash and equivalents: $796MQ2'23, Long-term debt: $206MQ3'23, Cash and equivalents: $899MQ3'23, Long-term debt: $152MQ3'23Q4'23, Cash and equivalents: $854MQ4'23, Long-term debt: $73MQ1'24, Cash and equivalents: $602MQ1'24, Long-term debt: $73MQ1'24Q2'24, Cash and equivalents: $446MQ2'24, Long-term debt: $73MQ3'24, Cash and equivalents: $491MQ3'24, Long-term debt: $203MQ3'24Q4'24, Cash and equivalents: $485MQ4'24, Long-term debt: $203MQ1'25, Cash and equivalents: $404MQ1'25, Long-term debt: $203MQ1'25Q2'25, Cash and equivalents: $510MQ2'25, Long-term debt: $203MQ3'25, Cash and equivalents: $629MQ3'25, Long-term debt: $203MQ3'25Q4'25, Cash and equivalents: $791MQ4'25, Long-term debt: $203MQ1'26, Cash and equivalents: $521MQ1'26, Long-term debt: $203MQ1'26Q2'26, Cash and equivalents: $436MQ2'26, Long-term debt: $203MQ3'26, Cash and equivalents: $464MQ3'26, Long-term debt: $203MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

West Pharmaceutical Services, Inc. income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 23, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 24, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue875872845805805767698749+8.7%
Cost of revenue527543549501510493466475+3.3%
Gross profit347329296304294274232274+18.0%
Research and development1820162217191619+7.0%
Selling, general and administrative113118100107103968885+9.9%
Operating income267179177157168154107160+59.5%
Other income (expense)000000000.0%
Pretax income268180180162172157111165+55.7%
Income tax5832453334302437+70.6%
Net income21415413913214013290130+52.9%
Diluted EPS ($)3.022.151.92—1.921.821.23—+57.3%
Diluted shares (millions)717172—737373——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

West Pharmaceutical Services, Inc. balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 23, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 24, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents464436521791629510404485−26.2%
Short-term investments—————————
Total current assets1,8171,8081,8271,9781,8231,6811,4581,538−0.4%
Total assets4,0614,0764,1104,2704,1063,9533,6183,643−1.1%
Total current liabilities644641674655635605527550+1.4%
Long-term debt203203203203203203203203+0.1%
Total liabilities1,0931,0861,1191,0941,0541,024935961+3.6%
Stockholders’ equity2,9682,9902,9903,1763,0522,9292,6832,682−2.7%
Shares outstanding (millions)7070717272727272—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 29, 2026.

West Pharmaceutical Services, Inc. cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 29, 2026Q2 FY2026ended Jun 30, 2026filed Jul 23, 2026Q1 FY2026ended Mar 31, 2026filed Apr 23, 2026Q4 FY2025ended Dec 31, 2025filed Feb 17, 2026Q3 FY2025ended Sep 30, 2025filed Oct 23, 2025Q2 FY2025ended Jun 30, 2025filed Jul 24, 2025Q1 FY2025ended Mar 31, 2025filed Apr 24, 2025Q4 FY2024ended Dec 31, 2024filed Feb 18, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow19012490251197177129190−3.9%
Capital expenditures39434376637571105−38.2%
Free cash flow (CFO − capex)15081471751341025885+12.3%
Depreciation and amortization4646454743414041+6.7%
Share repurchases23115729800113454—
Dividends paid1616161615151515+2.6%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 17, 2026.

Income statement

West Pharmaceutical Services, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 22, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Mar 1, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Revenue3,0742,8932,9502,8872,8322,1471,8401,7171,5991,5091,4001,4211,3681,2661,1921,1051,0561,051
Cost of revenue1,9701,8951,8211,7511,6561,3791,2341,1721,0861,008944974934879853787752749
Gross profit1,1049991,1291,1361,176768606545513501456448435388339318304303
Research and development746968595347394039373437383329242019
Selling, general and administrative394339353317363302273263246240233229235218191188178159
Operating income5855706767347524072972402261951291821621351109198124
Other income (expense)(1)(1)3(51)(3)(6)(5)032————400—
Pretax income601586698680749401292241222190116169147109937583110
Income tax12210812211510773594181542647403324141424
Net income494493593586662346242207151144961271128176657386
Diluted EPS ($)6.796.697.887.738.674.573.212.741.991.911.301.751.571.151.080.94*1.06*1.25*
Diluted shares (millions)73747576767675757675747371727473*73*72*

Balance sheet

West Pharmaceutical Services, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 22, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Mar 1, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Cash and equivalents791485854894763616439337236203275255230162921108387
Short-term investments————————————812271——
Total current assets1,9781,5381,9361,9201,7421,3741,059894744642674659651557472437397—
Total assets4,2703,6433,8303,6173,3142,7942,3411,9791,8631,7171,6951,6701,6701,5641,3991,2941,271—
Total current liabilities655550672519594503342284280241314253237262243170171—
Long-term debt20320373207209253255196197226229308371379299358379—
Total liabilities1,094961949932978939768583583599671713765835744669692—
Stockholders’ equity3,1762,6822,8812,6852,3351,8551,5731,3961,280—————————
Shares outstanding (millions)7272737474747474747372717069*—67*——

Cash flow statement

West Pharmaceutical Services, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 17, 2026FY2024ended Dec 31, 2024filed Feb 18, 2025FY2023ended Dec 31, 2023filed Feb 20, 2024FY2022ended Dec 31, 2022filed Feb 21, 2023FY2021ended Dec 31, 2021filed Feb 22, 2022FY2020ended Dec 31, 2020filed Feb 23, 2021FY2019ended Dec 31, 2019filed Feb 24, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 26, 2016FY2014ended Dec 31, 2014filed Feb 25, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Mar 1, 2012FY2010ended Dec 31, 2010filed Feb 28, 2011FY2009ended Dec 31, 2009filed Aug 5, 2010FY2008ended Dec 31, 2008filed Aug 5, 2010
Operating cash flow755653777724584473367289263219212183221187131138138135
Capital expenditures2863773622852531741261051311701321121521319571105139
Free cash flow (CFO − capex)4692764154393312982411841334981716956356733(4)
Depreciation and amortization171155137121122109103104979190908577767368—
Share repurchases1345614382031371168371745200—54215
Dividends paid615957545148454239363229272523222019

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$5M
6 sales by 1 insider; officers and directors $5M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$7M
8 sales by 2 insiders; officers and directors $7M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 15, 2026Favorite Annette FSr. VP & Chief HR Officeroption exercise2,524$89.64$226K24,342Sep 15, 2026
Sep 15, 2026Favorite Annette FSr. VP & Chief HR Officeropen-market sale10b5-12,524$365.00$921K21,818Sep 15, 2026
Sep 14, 2026Favorite Annette FSr. VP & Chief HR Officeroption exercise2,500$89.64$224K24,318Sep 15, 2026
Sep 14, 2026Favorite Annette FSr. VP & Chief HR Officeropen-market sale10b5-12,500$355.00$888K21,818Sep 15, 2026
Sep 11, 2026Favorite Annette FSr. VP & Chief HR Officeroption exercise2,500$89.64$224K24,318Sep 15, 2026
Sep 11, 2026Favorite Annette FSr. VP & Chief HR Officeropen-market sale10b5-12,500$345.00$863K21,818Sep 15, 2026
Sep 8, 2026Favorite Annette FSr. VP & Chief HR Officeroption exercise2,817$83.47$235K19,662Sep 10, 2026
Sep 8, 2026Favorite Annette FSr. VP & Chief HR Officeropen-market sale2,817$340.81$960K16,845Sep 10, 2026
Sep 8, 2026Favorite Annette FSr. VP & Chief HR Officeroption exercise2,818$83.47$235K19,663Sep 10, 2026
Sep 8, 2026Favorite Annette FSr. VP & Chief HR Officeropen-market sale2,818$340.81$960K16,845Sep 10, 2026
Sep 8, 2026Favorite Annette FSr. VP & Chief HR Officeroption exercise2,500$89.64$224K19,345Sep 10, 2026
Sep 8, 2026Favorite Annette FSr. VP & Chief HR Officeropen-market sale2,500$340.81$852K16,845Sep 10, 2026
Aug 11, 2026McMahon Robert W.SVP & Chief Financial Officeroption exercise794——3,775Aug 12, 2026
Aug 11, 2026McMahon Robert W.SVP & Chief Financial Officertax withholding346$351.37$121K3,429Aug 12, 2026
Aug 11, 2026McMahon Robert W.SVP & Chief Financial Officeroption exercise6,355——9,784Aug 12, 2026
Aug 11, 2026McMahon Robert W.SVP & Chief Financial Officertax withholding2,764$351.37$971K7,021Aug 12, 2026
May 12, 2026Campbell Shane AldenSVP, Proprietary Segmentoption exercise296——358May 14, 2026
May 12, 2026Campbell Shane AldenSVP, Proprietary Segmenttax withholding84$312.07$26K274May 14, 2026
May 12, 2026Campbell Shane AldenSVP, Proprietary Segmentoption exercise474——748May 14, 2026
May 12, 2026Campbell Shane AldenSVP, Proprietary Segmenttax withholding135$312.07$42K613May 14, 2026
May 4, 2026Pucci PaoloDirectoraward791$0.00—11,854May 6, 2026
May 4, 2026Michels Douglas ADirectoraward791$0.00—46,496May 6, 2026
May 4, 2026Lockhart Stephen HDirectoraward791$0.00—3,523May 6, 2026
May 4, 2026Lai Goldman MylaDirectoraward791$0.00—20,435May 6, 2026
May 4, 2026Keller Deborah LDirectoraward791$0.00—11,560May 6, 2026

Full insider history for West Pharmaceutical Services, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held WST in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded WST by quarter.

FundManagerQuarterValueSharesWeightMove
Gates Foundation TrustMichael LarsonQ2 2026$160M444,5000.46%held
Baron Capital GroupRon BaronQ2 2026$59M164,1740.09%trimmed −17.8%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
WEST PHARMACEUTICAL SERVICES, INC., CIK 105770 on EDGAR
Extract generated
October 30, 2026
Withheld
none
Repaired
3 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2018, other income FY2022, other income FY2023
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss, ProfitLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated October 30, 2026.

JSON file
/data/financials/WST.json